Caffeine for Cognition in Alzheimer's Disease (NCT04570085)
Overview
flowchart TD
Caffeine_for_Cognition_in_AD__["Caffeine for Cognition in AD NCT04570085"]
Caffeine_for_Cognition_in_AD__["Cognition"]
Caffeine_for_Cognition_in_AD__ -->|"related to"| Caffeine_for_Cognition_in_AD__
style Caffeine_for_Cognition_in_AD__ fill:#81c784,stroke:#333,color:#000
Caffeine_for_Cognition_in_AD__["Alzheimer"]
Caffeine_for_Cognition_in_AD__ -->|"related to"| Caffeine_for_Cognition_in_AD__
style Caffeine_for_Cognition_in_AD__ fill:#81c784,stroke:#333,color:#000
Caffeine_for_Cognition_in_AD__["Phase"]
Caffeine_for_Cognition_in_AD__ -->|"related to"| Caffeine_for_Cognition_in_AD__
style Caffeine_for_Cognition_in_AD__ fill:#81c784,stroke:#333,color:#000
style Caffeine_for_Cognition_in_AD__ fill:#4fc3f7,stroke:#333,color:#000
NCT04570085 is a Phase 3 randomized, double-blind, placebo-controlled clinical trial investigating the effects of caffeine supplementation on cognitive function in patients with Alzheimer's disease (AD). This study represents a significant effort to evaluate whether caffeine—a widely consumed psychoactive substance—can provide therapeutic benefits for neurodegeneration["@nct04570085"].
The trial enrolled 248 participants and has been completed, contributing valuable data to the understanding of caffeine's potential neuroprotective effects in AD.
...Caffeine for Cognition in Alzheimer's Disease (NCT04570085)
Overview
Mermaid diagram (expand to render)
NCT04570085 is a Phase 3 randomized, double-blind, placebo-controlled clinical trial investigating the effects of caffeine supplementation on cognitive function in patients with Alzheimer's disease (AD). This study represents a significant effort to evaluate whether caffeine—a widely consumed psychoactive substance—can provide therapeutic benefits for neurodegeneration["@nct04570085"].
The trial enrolled 248 participants and has been completed, contributing valuable data to the understanding of caffeine's potential neuroprotective effects in AD.
<div class="infobox infobox-trial">
<table>
<tr><th colspan="2">NCT04570085 Trial Details</th></tr>
<tr><td>Phase</td><td>Phase 3</td></tr>
<tr><td>Intervention</td><td>Caffeine supplementation</td></tr>
<tr><td>Participants</td><td>248</td></tr>
<tr><td>Status</td><td>Completed</td></tr>
<tr><td>Primary Outcome</td><td>Cognitive measures (ADAS-Cog, MMSE)</td></tr>
</table>
</div>
Background and Rationale
Epidemiological Evidence
Multiple epidemiological studies have suggested an association between coffee consumption and reduced risk of cognitive decline and dementia[@coffee_ad_2018][@coffee_mci_2024]:
- Regular coffee consumption is associated with 30-40% reduced risk of developing AD in observational studies
- Higher caffeine intake correlates with better cognitive performance in elderly populations
- The association appears dose-dependent, with moderate consumption (3-5 cups/day) showing optimal benefits
Mechanism of Action
Caffeine exerts neuroprotective effects through multiple pathways[@caffeine_2019][@caffeine_mechanism_2025]:
Adenosine Receptor Antagonism: Caffeine primarily acts as a non-selective antagonist of adenosine A1 and A2A receptors (A2AR). This blockade:
- Reduces neuronal inhibition, enhancing excitability
- Modulates neurotransmitter release
- Alters sleep-wake cycles
Anti-inflammatory Effects: A2A receptor antagonism reduces neuroinflammation by:
- Inhibiting pro-inflammatory cytokine production
- Reducing microglial activation
- Decreasing oxidative stress[@a2a_2023]
Amyloid Interaction: Caffeine attenuates amyloid-beta (Aβ)-induced neurotoxicity:
- Reduces Aβ production through BACE1 inhibition
- Enhances Aβ clearance
- Protects against Aβ-induced synaptic dysfunction[@caffeine_ amyloid_2021]
Synaptic Plasticity: Caffeine enhances memory through:
- Long-term potentiation (LTP) facilitation
- Improved dendritic spine density
- Enhanced neurotransmitter signaling
Neuroprotection: Additional mechanisms include:
- Mitochondrial function preservation
- Autophagy induction
- Tau phosphorylation modulation
Adenosine A2A Receptor Role in AD
The A2A receptor has emerged as a particularly important target in AD[@adenosine_2020]:
- A2A receptors are upregulated in AD brain tissue
- A2A activation promotes neuroinflammation and amyloidogenesis
- A2A blockade improves cognition in animal models of AD
- A2A antagonists (including caffeine) show promise as disease-modifying agents
Study Design
Trial Structure
- Design: Randomized, double-blind, placebo-controlled
- Duration: 52 weeks (1 year)
- Arms:
- Active: Caffeine supplementation (dose to be determined)
- Placebo: Matched inactive comparator
Outcome Measures
Primary Endpoints:
- Cognitive function assessed by ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)
- Global cognition measured by MMSE (Mini-Mental State Examination)
Secondary Endpoints:
- Functional capacity (ADL scores)
- Behavioral symptoms (NPI - Neuropsychiatric Inventory)
- Safety and tolerability
- Biomarker changes (Aβ levels, tau, inflammatory markers)
Inclusion Criteria
- Clinical diagnosis of probable Alzheimer's disease
- MMSE score between 12-26 (mild to moderate AD)
- Age 65-85 years
- Stable cholinesterase inhibitor or memantine use permitted
- Caregiver availability for compliance assistance
Clinical Findings
Efficacy Results
While detailed results are being analyzed, the trial provides critical data on[@caffeine_cognition_2022][@caffeine_trial_2025]:
- Cognitive outcomes in caffeine-treated vs. placebo groups
- Dose-response relationships
- Time course of effects
- Subgroup analyses (age, disease stage, genetic status)
Safety Profile
Caffeine has a well-characterized safety profile at therapeutic doses:
- Generally well-tolerated at doses up to 400 mg/day in elderly
- Common side effects include insomnia, jitteriness, and GI upset
- Cardiovascular considerations in patients with arrhythmias
- Drug interactions with anticoagulants, stimulants
Biomarker Findings
The trial likely collected data on:
- CSF Aβ42 and tau levels
- Plasma inflammatory markers (IL-6, TNF-α)
- Neuroimaging (MRI volumetry, PET amyloid)
- Adenosine receptor expression
Implications and Future Directions
Repurposing Potential
This trial represents an important example of drug repurposing:
- Caffeine is already FDA-approved as a food additive
- Well-characterized pharmacokinetics and safety
- Low cost compared to novel therapeutics
- Potential for rapid clinical translation
Combination Therapy
Future directions may include:
- Caffeine with standard AD treatments (cholinesterase inhibitors, anti-amyloid therapies)
- Caffeine with other lifestyle interventions (diet, exercise)
- Personalized medicine based on genetic polymorphisms in adenosine metabolism
Research Gaps
Remaining questions include:
- Optimal caffeine dose and formulation
- Timing of intervention (preclinical vs. clinical)
- Long-term effects (>1 year)
- Effects on disease progression vs. symptomatic benefit
- Mechanism-specific contributions
Related Pages
- [Adenosine A2A Receptor](/entities/adenosine-a2a-receptor)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Coffee and Neurodegeneration](/entities/coffee-consumption)
Similar Trials
- [Semorinemab](/therapeutics/semorinemab) - anti-tau antibody
- [Lecanemab](/entities/lecanemab) - anti-amyloid antibody
- [Other caffeine trials in MCI](/clinical-trials/caffeine-mci)
References
[ClinicalTrials.gov: NCT04570085](https://clinicaltrials.gov/ct2/show/NCT04570085)
[Ostrom et al., Coffee consumption and risk of dementia (2018)](https://pubmed.ncbi.nlm.nih.gov/29922757/)
[Ramos et al., Caffeine neuroprotective effects (2019)](https://pubmed.ncbi.nlm.nih.gov/31154012/)
[Chen et al., Adenosine A2A receptors in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32980456/)
[Kumar et al., Caffeine attenuates Aβ toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/34044023/)
[Sanchez-Valle et al., Caffeine and cognitive performance (2022)](https://doi.org/10.1016/j.jalz.2022.01.012)
[Li et al., A2A receptor blockade in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/36984812/)
[Santos et al., Coffee consumption and MCI (2024)](https://pubmed.ncbi.nlm.nih.gov/39562456/)
[Miller et al., Caffeine supplementation Phase 3 results (2025)](https://doi.org/10.1186/s13195-025-01456-w)
[Zhang et al., Mechanisms of caffeine neuroprotection (2025)](https://doi.org/10.1016/j.arr.2025.02.003)Historical Context and Caffeine Research Timeline
The investigation of caffeine as a potential therapeutic agent for neurodegenerative diseases has evolved over several decades:
1980s-1990s: Early epidemiological studies first noted an association between coffee consumption and reduced dementia risk. These observational findings, while intriguing, could not establish causality.
2000s: Research began to characterize the molecular mechanisms underlying caffeine's neuroprotective effects. Key discoveries included A2A receptor-mediated anti-inflammatory pathways and amyloidogenesis inhibition.
2010s: Several preclinical studies demonstrated that caffeine could improve cognitive performance in animal models of AD and PD. This evidence supported advancement to human trials.
2020s: Multiple clinical trials, including NCT04570085, have evaluated caffeine in various neurodegenerative contexts. Results from these trials are now informing clinical practice guidelines.
Understanding caffeine's pharmacokinetic properties is essential for optimizing its therapeutic potential:
- Absorption: Rapidly absorbed from the gastrointestinal tract with nearly 100% bioavailability
- Distribution: Crosses the blood-brain barrier readily, achieving CSF concentrations approximately 10-20% of plasma levels
- Metabolism: Primarily metabolized by hepatic cytochrome P450 enzymes (CYP1A2)
- Half-life: Approximately 5-6 hours in adults, extended in elderly individuals and those with liver disease
- Elimination: Renal excretion of metabolites
Factors affecting caffeine metabolism include age, genetic polymorphisms in CYP1A2, concurrent medications, and liver function.
Safety Considerations in Elderly Populations
Caffeine use in elderly AD patients requires special consideration:
Cardiovascular: Caffeine may increase heart rate and blood pressure; monitoring recommended in patients with arrhythmias or hypertension
Sleep: Caffeine can disrupt sleep architecture, which is already commonly disturbed in AD; avoid consumption in the evening
Bone Health: Caffeine can increase calcium excretion; relevant for patients with osteoporosis
Drug Interactions: Caffeine may interact with anticoagulants, stimulants, and certain AD medications
Tolerance: Regular caffeine consumers may experience withdrawal symptoms if caffeine is suddenly discontinued